arrow
P

Pei-Chien Tsai

kaohsiung medical university
H指数:35
被引数:3,966

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The Clinical Utility of Adding Laminin Gamma 2 Monomer to the PAGE‐B Score for Hepatocellular Carcinoma Surveillance in Chronic Hepatitis B

在慢性乙型肝炎患者中,将层粘连蛋白γ2单体加入PAGE-B评分以用于肝细胞癌监测的临床应用价值

2026-10-080
PRE
Cardiometabolic Biomarkers for Disease Severity Prediction in Metabolic Dysfunction-Associated Steatotic Liver Disease

代谢功能障碍相关脂肪性肝病中用于疾病严重程度预测的心血管代谢生物标志物

2026-09-130
OAAI
Impact of Cardiometabolic Risk Factors and Steatotic Liver Disease on Liver-Related Outcomes in Patients With Chronic Hepatitis C After Curative Antiviral Therapy

慢性丙型肝炎患者经治愈性抗病毒治疗后,心血管代谢危险因素和脂肪性肝病对肝脏相关结局的影响

2026-04-220
OAAI
High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis C

高正常值范围及异常丙氨酸转氨酶水平与慢性丙型肝炎治疗后肝癌风险增加相关

2026-04-012
OAAI
Revisiting unmet needs in clinical research on direct-acting antiviral therapy for HCC patients: Correspondence to letter to the editor on Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study

重新审视直接抗病毒疗法在HCC患者临床研究中的未满足需求:关于“HCV相关肝细胞癌患者的直接抗病毒疗法:一项全国性队列研究”的读者来信的回复

2026-01-011
OA
Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage: Correspondence to editorial on Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study

新兴证据支持对早期阶段之外的HCC患者进行直接抗病毒治疗:致编辑关于HCV相关肝细胞癌患者直接抗病毒治疗的信

2026-01-011
OA
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study

丙型肝炎病毒清除对伴有或不伴有活动性肝细胞癌患者的生存影响:一项全国性队列研究

2025-11-140
PRE
Impact of Concurrent Steatotic Liver Disease and Chronic Hepatitis B on Treatment Response to Nucleos(t)ide Analogs

合并脂肪性肝病和慢性乙型肝炎对核苷(酸)类似物治疗反应的影响

2025-10-010
PRE
Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort study

代谢功能障碍对核苷(酸)类似物治疗慢性乙型肝炎反应的影响:一项回顾性多中心REAL-B队列研究

2025-08-110
PREAI
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in Taiwan

Sofosbuvir/Velpatasvir治疗对2型糖尿病和慢性丙型肝炎患者肝外表现的影响: 来自台湾全国丙型肝炎病毒登记处的见解

2025-06-200
OAAI
Impact of Hepatitis C Virus Clearance on Cardiovascular Risk: A Real-World Experience From the Nationwide Taiwan Hepatitis C Virus Registry

丙型肝炎病毒清除对心血管风险的影响: 来自全国台湾丙型肝炎病毒登记处的真实经验

2025-05-240
OAAI
Distribution, Characteristics, and Natural History of Diverse Types of Indeterminate Chronic Hepatitis B: A REAL-B Study

不同类型的不确定慢性乙型肝炎的分布、特征及自然史:REAL-B研究

2025-05-210
PRE
Mitochondrial mt12361A>G increased risk of metabolic dysfunction-associated steatotic liver disease among non-diabetes

线粒体mt12361A>G增加非糖尿病患者代谢功能障碍相关的脂肪性肝病的风险

2025-03-140
PRE